C12Y 302/01035
Hyaluronoglucosaminidase , i.e. hyaluronidase
Official title: Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
C12Y302/01035 (Hyaluronoglucosaminidase , i.e. hyaluronidase) appears on 178 US grants and 367 published applications in this corpus.
Search patents in C12Y- Granted patents
- 178
- Published applications
- 367
- Assignees
- 120
- Inventors
- 509
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 4 |
| 2005 | 0 | 2 |
| 2006 | 2 | 2 |
| 2007 | 0 | 2 |
| 2008 | 1 | 3 |
| 2009 | 1 | 11 |
| 2010 | 5 | 5 |
| 2011 | 4 | 9 |
| 2012 | 4 | 14 |
| 2013 | 10 | 14 |
| 2014 | 9 | 15 |
| 2015 | 6 | 11 |
| 2016 | 6 | 10 |
| 2017 | 14 | 18 |
| 2018 | 10 | 15 |
| 2019 | 12 | 26 |
| 2020 | 9 | 22 |
| 2021 | 11 | 19 |
| 2022 | 9 | 22 |
| 2023 | 10 | 34 |
| 2024 | 25 | 31 |
| 2025 | 12 | 41 |
| 2026 | 12 | 36 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Digital microbiology15 Sep 2026US 12,735,735 B2Bio-Rad Europe GmbH
- Combination therapy with antibody-drug conjugates and hyaluronidases14 Jul 2026US 12,678,492 B2Halozyme, Inc.
- Hyaluronic acid-producing recombinant cells14 Jul 2026US 12,680,121 B2Givaudan SA
- Subcutaneous anti-HER2 antibody formulations and uses thereof30 Jun 2026US 12,667,616 B2Genentech, Inc.
- Hyaluronidase enzyme formulations for high volume administration26 May 2026US 12,636,350 B2Halozyme, Inc.
- Egfr and c-met binding agent variants and methods of use1 Oct 2026US 2026/0297201 A1Janssen Biotech, Inc.
- Pharmaceutical composition for subcutaneous administration containing human hyaluronidase ph20 variant and drug1 Oct 2026US 2026/0297215 A1Alteogen, Inc.
- Ph20 polypeptide variants, formulations and uses thereof1 Oct 2026US 2026/0297551 A1Halozyme, Inc.
- Combination therapy with antibody-drug conjugates and hyaluronidases17 Sep 2026US 2026/0273030 A1Halozyme, Inc.
- Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof17 Sep 2026US 2026/0273052 A1Genentech, Inc.
Most cited
By later US patents
- Method for treating benign prostatic hypertrophy159US 5,116,615 AImmunolytics Inc. · 1992
- Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof135US 7,767,429 B2Halozyme, Inc. · 2010
- Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases83US 7,871,607 B2Halozyme, Inc. · 2011
- Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof81US 8,431,380 B2Halozyme, Inc. · 2013
- Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases76US 7,829,081 B2Halozyme, Inc. · 2010